Altered Secondary Myogenesis in Transgenic Animals Expressing the Neural Cell Adhesion Molecule under the Control of a Skeletal Muscle α-Actin Promoter

Sam Fazeli,* Dominic J. Wells,‡ Carl Hobbs,* and Frank S. Walsh*

*Department of Experimental Pathology, UMDS, Guy’s Hospital, London SE1 9RT, United Kingdom; and ‡Department of Veterinary Basic Sciences, The Royal Veterinary College, London NW1 0TU, United Kingdom

Abstract. The majority of skeletal muscle fibers are generated through the process of secondary myogenesis. Cell adhesion molecules such as NCAM are thought to be intricately involved in the cell-cell interactions between developing secondary and primary myotubes. During secondary myogenesis, the expression of NCAM in skeletal muscle is under strict spatial and temporal control. To investigate the role of NCAM in the regulation of primary–secondary myotube interactions and muscle fusion in vivo, we have examined muscle development in transgenic mice expressing the 125-kD muscle-specific, glycosylphosphatidylinositol-anchored isoform of human NCAM, under the control of a human skeletal muscle α-actin promoter that is active from about embryonic day 15 onward. Analysis of developing muscle from transgenic animals revealed a significantly lower number of myofibers encased by basal lamina at postnatal day 1 compared with non-transgenic littermates, although the total number of developing myofibers was similar. An increase in muscle fiber size and decreased numbers of VCAM-1-positive secondary myoblasts at postnatal day 1 was also found, indicating enhanced secondary myoblast fusion in the transgenic animals. There was also a significant decrease in myofiber number but no increase in overall muscle size in adult transgenic animals; other measurements such as the number of nuclei per fiber and the size of individual muscle fibers were significantly increased, again suggesting increased secondary myoblast fusion. Thus the level of NCAM in the sarcolemma is a key regulator of cell-cell interactions occurring during secondary myogenesis in vivo and fulfills the prediction derived from transfection studies in vitro that the 125-kD NCAM isoform can enhance myoblast fusion.

Vertebrate skeletal myogenesis occurs in at least two distinct steps. Myoblasts align and fuse synchronously to form primary myotubes (Kelly and Zacks, 1969; Ontell and Kozeka, 1984a,b). Secondary myotubes then begin to form under the basal lamina of primary myotubes. With time, secondary myotubes become indistinguishable from primary myotubes, as they separate and acquire their own basal lamina. Primary myotubes then act as a scaffold for further rounds of myogenesis. In this way the majority of adult muscle fibers are composed of secondary myotubes.

A number of cell adhesion molecule (CAM) families have been implicated in myoblast fusion and myotube interactions (Walsh and Doherty, 1994). These include various members of the cadherin family of calcium-dependent adhesion molecules (Knudsen, 1990; Donalies et al. 1991; Takeichi, 1991; Hahn and Covault, 1992; Mege et al., 1992; Moore and Walsh, 1993; Zeschnigk et al., 1995), the integrin family of cell–cell and cell–matrix adhesion molecules (Menko and Boettiger, 1987; Rosen et al., 1992), and neural cell adhesion molecule (NCAM) (Covault and Sanes, 1986; Dickson et al., 1990; Knudsen et al., 1990; Tassin et al., 1991; Peck and Walsh, 1993).

NCAM is a member of the immunoglobulin superfamily of adhesion molecules. Use of alternative splicing gives rise to the main NCAM protein isoforms of 180, 140, and 120 kD (Walsh and Doherty, 1991). These differ in the length of their intracellular domains such that the transmembrane 180-kD isoform has a larger domain than the 140-kD isoform, while the 120-kD size class are attached to the cell membrane via a glycosylphosphatidylinositol (GPI) anchor. Additional diversity in structure is found in the extracellular portion of NCAM including the muscle specific domain (MSD) producing a 125-kD isoform of NCAM that is preferentially expressed in skeletal muscle (Dickson et al., 1987; Thompson et al., 1989), and a 10-amino acid
NCAM expression in skeletal muscle is developmentally regulated. The 180- and 140-kd isoforms are expressed in the myotome (Thiery et al., 1982; Lyons et al., 1992). After fusion the expression of these isoforms is repressed and the GPI-linked isoform (125 kD) is uniformly expressed on the surface of primary myotubes. As secondary myogenesis begins, however, NCAM is found concentrated at the site of membrane apposition of primary and secondary myotubes (Covault and Sanes, 1986), possibly indicating a role for NCAM in the control of secondary myogenesis. NCAM expression increases in parallel with myotube formation (Moore et al., 1987) and is subsequently down-regulated in the adult (Moore and Walsh, 1985; Covault and Sanes, 1986). Perturbation of neuromuscular activity in the chick, by in vivo injection of botulinum toxin, leads to changes in the normal pattern of expression of NCAM and N-cadherin and is also accompanied by an arrest of secondary myogenesis (Fredette et al., 1993). A direct correlation between the changes in CAM expression and the effects on myogenesis cannot, however, be made since blockade of neuromuscular activity may have a number of other unknown consequences.

Many studies on the role of CAMs in muscle development have involved the use of in vitro cell culture systems (Dickson et al., 1990; Knudsen et al., 1990; Tassin et al., 1991; Hahn and Covault, 1992; Mege et al., 1992; Peck and Walsh, 1993). For NCAM, transfection-based studies using the C2 muscle cell line have provided data that show a role in the regulation of myoblast fusion (Peck and Walsh, 1993). Expression of the 125-kd, GPI-anchored NCAM isoform in particular led to a dramatic enhancement of fusion. It clearly would be of interest to be able to test whether CAMs have a similar role to play in vivo. There are presently a number of possible strategies for directly assessing the function of molecules in vivo. Homologous recombination can be used to generate animals unable to make the proteins of interest. Alternatively, ectopic expression of a molecule, or modified forms of it, may give insights into its function. We chose the second strategy to test the hypothesis that the levels of NCAM in developing myotubes may regulate primary–secondary myotube interactions, which is an important step in the development of the full complement of myofibers and myoblast fusion. As myofiber interactions likely involve the operation of a number of adhesion molecules including VCAM-1 and VLA4 (Rosen et al., 1992) and different cadherins such as N-cadherin (Hahn and Covault, 1992) and M-cadherin (Donalies et al., 1991; Moore and Walsh, 1993; Zeschnigk et al., 1995), it seemed unlikely that removal of NCAM expression by homologous recombination methods would have dramatic functional consequences. Also, since NCAM is expressed in the developing and adult nervous system and heart, any observed skeletal muscle phenotype in animals lacking a functional NCAM gene may be secondary to perturbations at other sites. Mice in which the NCAM gene has been inactivated using homologous recombination have been produced (Cremer et al., 1994), but analysis of myogenesis has not yet been reported.

Expression of the 125-kd isoform of human NCAM (hNCAM), under the control of the skeletal α-actin promoter, recapitulates some aspects of the developmental profile of expression of the endogenous isoform. Both the transgene and the endogenous isoform are expressed and colocalize in developing myotubes. While the expression of the transgene persists into adulthood, endogenous NCAM expression is down-regulated postnatally associated with the development of neuromuscular interactions (Moore and Walsh, 1985; Covault and Sanes, 1986). Muscles in adult transgenic animals were found to have a significantly reduced number of myofibers but myofiber size and the number of nuclei per fiber were increased. The reduction in muscle fiber number in the adult was found to be the result of an impairment of secondary myotube separation from primary myotubes beginning at PND1. A significant depletion in VCAM-1–positive secondary myoblasts was also found at this age which, taken together with the increase in myofiber size and the number of nuclei per fiber, was indicative of enhanced fusion induced by expression of the transgene.

**Material and Methods**

**Generation of Transgenic Animals**

The SV-40 ‘t’ intron was cloned into the Bluescript vector (pBSK II+; Stratagene, La Jolla, CA), the multiple cloning site of which had been previously modified to aid construction (pBSV40). A cDNA for the 125-kd, GPI-anchored isoform of hNCAM (with line AV21) or without [lines ANS and 14] the VASE exon [Barton et al., 1988; Small and Akeson, 1990] was then directionally cloned into pBSV40. The human skeletal muscle-specific α-actin promoter (2.2kbHSA-CAT, a gift from Dr. Edna Hardeman, Children's Medical Research Institute, Sydney, Australia; Brennan and Hardeman, 1993), containing 2.2 kb of the 5' region of the gene, was cloned upstream of the NCAM cDNA (pACT125; see Fig. 1). The fragment for microinjection was released with BssHII and purified by gel electrophoresis and glass milk extraction (Qiaex; QIAGEN, Hilden, Germany). DNA was injected into a pronucleus of fertilized oocytes of C57Bl/10 × CBA/J at 1–2 ng/μl, and the eggs cultured overnight. Two cell embryos were then implanted into pseudopregnant recipients and the G0 progeny were analyzed by PCR and Southern blotting of genomic DNA, as described below.

**Polymerase Chain Reaction**

PCR analysis was routinely used to detect the presence of the transgene. PCR was performed using 5' AACCCGCTCTTTCTTTGTTACAG 3'

```tex
\begin{center}
\begin{tikzpicture}
\node at (0,0) {alpha-actin promoter};
\node at (1,0) {NCAM cDNA};
\node at (2,0) {SV40 t};
\node at (3,0) {BssHII};
\node at (4,0) {BglII};
\node at (5,0) {BglII};
\node at (6,0) {BglII};
\node at (7,0) {BssHII};
\node at (0,-0.5) {800 bp};
\end{tikzpicture}
\end{center}
```

Figure 1. Schematic representation of the expression cassette used for generation of transgenic animals. NCAM cDNA encoding the GPI-anchored isoform including the MSD region and either with or without the VASE exon were cloned downstream of the 2.2-kb α-actin promoter, in a modified pBSK II+ vector (Stratagene). The construct also includes the SV-40 ‘t’ intron and polyadenylation signals. The fragment used for injection was liberated by digestion with BssHII. Arrows indicate the position of the forward (+) and reverse (−) primers used for PCR analysis of genomic DNA. Southern analysis was performed on BglII-digested genomic DNA, resulting in a 1-kb product specific to the transgene.
as forward primer corresponding to position −466 to −442 in the α-actin promoter (Brennan and Hardeman, 1993) and 5′ CGGTGCTGGGA-
AACAATATCCACC 3′ as the reverse primer corresponding to +226 to +202 in the NCAM cDNA (see Fig. 1A), giving a product of 692 bp (data
not shown). For use in Northern blot analysis (see below), a DNA frag-
ment was obtained by reverse transcriptase PCR (Cavicchioli et al.,
1991) of mouse muscle RNA extracted using the NP-40 lysis method (Sambrook et al., 1989). Primers complementary to positions 406–429
(forward: 5′ CCATCTACACGGCAACATCGAGC 3′) and 1613–1639
(reverse: 5′ ATTCAGCTGGACTGGTCCAATA 3′) of mouse NCAM
cDNA encoding the GPI-anchored, 120-kd isoform (Barbas et al., 1988)
were used.

Southern Blotting
Genomic DNA was obtained by proteinase K digestion of tail biopsies fol-
lowed by phenol/chloroform extraction (Sambrook et al., 1989). 10 µg of
DNA was digested overnight with BglII, which liberates a 1-kb fragment
specific to the transgene (see Fig. 2A) and fractionated by agarose gel
electrophoresis. DNA concentration was estimated spectrofluorometrically
and equal loading of tracks was assessed by ethidium bromide staining
of the gel. After alkaline denaturation, the DNA was transferred to
Biodyne A membranes (Pall, Portsmouth, UK) by capillary transfer and
covalently bound to the membrane by UV irradiation. After prehybridiza-
tion of membranes, a gel-purified BglII fragment internal to the hNCAM
cDNA and labeled with [32p]dCTP by nick translation (Boehringer Mann-
heim, Mannheim, Germany), was used for hybridization at 65°C over-
night. The hybridization buffer was 6 × SSC, 5% Denhardt’s, 0.5% SDS,
and 100 µg/ml herring sperm DNA. After hybridization, the membrane
was washed three times with 1 × SSC and 0.5% SDS at 65°C.

Northern Analysis
mRNA from transgenic animals and control 7-d denervated and nonde-
nervated hind leg muscles was obtained using the Fast Track mRNA puri-
fication kit (Invitrogen, Leek, Holland). 1 µg of mRNA was loaded on a 2.2 M
formaldehyde agarose gel and transferred to Biodyne A membranes by
capillary transfer (Sambrook et al., 1989). Equal loading of samples was
checked by ethidium bromide staining of the gel. The remainder of the

Western Blotting
Tissue samples were homogenized in 10 mM Tris-HCl (pH 7.4), 1 mM
EDTA, 1% NP-40 containing 5% aprotinin, and 1 mM PMSF. After incu-
vation for 20 min at 4°C, the homogenate was spun at 14,000 g for 15 min.
The supernatant was used for protein estimation (BCA; Pierce, Rockford,
IL) and further analysis. SDS-PAGE and Western transfer were carried
out using standard protocols. Briefly, proteins were fractionated on a
7.5% resolving gel and transferred to reinforced nitrocellulose membrane
(Schleicher and Schuell, Dassel, Germany). Membranes were routinely
stained with Ponceau S to ensure equal protein loading and transfer.

Figure 2. Analysis of transgenic status and expression level of founder mice. Three founder lines were analyzed in this series of experi-
ments: AN14, AV21, and AN5. (A) Southern blot analysis of these lines revealed that lines AN14 and AV21 each contained >100 cop-
ies of the transgene, whereas line AN5 contained ~30 copies. The arrow indicates the 1-kb fragment obtained by BglIII digestion of 10
µg of genomic DNA, hybridized to a random primed α-32P-labeled BglIII fragment obtained by digestion of hNCAM cDNA. Copy num-
bers were estimated by comparison of hybridization signal with a serial dilution of the purified probe. (B) Immunoblot analysis of
hNCAM expression in adult skeletal muscle obtained from each line. 40 µg protein was loaded in each well and protein loads were
checked by Ponceau S staining of nitrocellulose membranes before antibody reaction. Lines AN14 and AV21 express approximately
twice the level of hNCAM (125 kD, arrow) than line AN5. The blot also demonstrates the lower level of expression in a predomi-
nantly slow muscle (SOL, S) compared with an almost exclusively fast muscle (EDL, E). The smaller bands observed in some of the
samples are likely to be degradation products. (C) mRNA levels in adult quadriceps, examined by Northern blot analysis, show that
lines AN14 and AN5 express fivefold higher and equal levels of NCAM than the endogenous levels in 7-d denervated (DN) nontrans-
genic muscle. One major mRNA species of ~3.4 kb was detected in transgenic muscle in contrast to the ~2.7-kb band in the nontrans-
genic denervated muscle. No NCAM mRNA was detected in nondenervated control muscle (CON). 1 µg of purified mRNA was loaded
onto each lane and the mRNA load examined by ethidium bromide staining of the gel. The blot was hybridized to a mouse probe ob-
tained by RT-PCR of mouse RNA, giving a fragment equivalent to the BglIII fragment used for Southern blotting.
Morphometric Analysis of Adult Skeletal Muscle

The whole hind limb of PND1 animals or extensor-digitorum longus (EDL) and soleus (SOL) muscles of adult transgenic and nontransgenic littermates were dissected, placed in Cryoembed (Bright, Huntingdon, UK), and frozen in liquid nitrogen cooled isopentane. 5-μm cryostat sections were obtained from the mid-belly region of each muscle and either processed for immunohistochemistry or stained with haematoxylin and eosi (H and E). The radii of 200 fibers per section were measured using a camera lucida arrangement in conjunction with a digitizer pad. A personal computer (86B; Hewlett-Packard Co., Palo Alto, CA) was used with an IMAGAN basic quantitation program. Mean fiber radii and maximum fiber diameter over the minor axis were computed from closed loop and line length measurements of laminin-stained, paraffin-embedded sections, respectively. The data were then ranked and a frequency histogram generated. All analyses were double blind and confined to transgenic and nontransgenic littermates of the same sex. To reactivate endogenous NCAM gene expression, the hind limb was denervated by sectioning of the sciatic nerve. Muscle biopsies were obtained 7 d later, at which time the endogenous mouse NCAM expression is high (Covault and Sanes, 1985; Moore and Walsh, 1986). To estimate muscle size, the perimeter of each section was traced and the area was calculated. The total number of fibers in each muscle was calculated by counting the number of fibers in an area of 0.7 mm², corresponding to the sum of the area of eight different regions chosen randomly, and extrapolated using the area of the muscle section. The number of nuclei in each section, stained with H and E, was estimated in a similar way.

Results

Expression of hNCAM in Transgenic Animals and Analysis of Transgene Expression

We have used a human skeletal muscle α-actin promoter fused to a hNCAM cDNA encoding the 125-kd, GPI-anchored isoform (with and without the product of the VASE exon) to achieve high level expression of this isoform in the skeletal muscle of transgenic mice. PCR analysis initially was used to detect the presence of the transgene in founder mice. The PCR primers were specific to the transgene, with the forward primer in the promoter region and the reverse primer in the 5' region of the NCAM cDNA (Fig. 1). All founder mice were also verified to be transgenic by Southern blot analysis. Three founder lines were analyzed in this study: AN14, AV21, and AN5, and a representative Southern blot is shown (Fig. 2 A).

The level of protein expression in these lines, as determined by Western blot analysis, is shown in Fig. 2 B. Immunoblot analysis also showed differing levels of expression in the three lines in individual muscle types. In the predominantly fast EDL muscle there was higher expression than in the SOL which is a slow muscle. Fiber type differences in hNCAM expression can also be observed on immunostained sections of adult muscle (see below). Northern blotting revealed one major mRNA band in the AN14 and AN5 lines of ~3.4 kb, which is larger than that observed in the nontransgenic denervated muscle (~2.7 kb, Fig. 2 C). This difference is attributable to the splicing of the SV-40 ‘t’ intron at the 3’ end of the cDNA in the transgene (Fig. 1), which does not affect the size of the protein product but increases the RNA size.

The level of hNCAM mRNA in line AN5 is approximately equal to the level of endogenous NCAM mRNA in denervated adult muscle from nontransgenic animals (Fig. 2 C); denervation has been previously shown to reactivate N-CAM gene expression (Covault and Sanes, 1985; Moore and Walsh, 1985, 1986; Danillof et al., 1986). Comparison of protein expression levels in lines AN14 and AV21 with line AN5 (Fig. 2 B) indicates about a fivefold higher level of hNCAM in the former than in line AN5. Thus, lines AN14 and AV21 express approximately fivefold higher levels of NCAM protein than is found in denervated muscle from nontransgenic mice. The profile of hNCAM expression in various tissues from adult animals of line AN14 is shown in Fig. 3 A. The highest level of expression is in skeletal muscle, with heart and gut the only other tissues showing detectable expression. The developmental profile...
of expression of the transgene in these lines (Fig. 3 B) revealed an increase in expression between PND1 and adult muscle such that at PND1 the expression level of the transgene in lines AN14 and AV21 is estimated to be approximately equal to that of the endogenous protein. Our data are similar to the published profile and developmental expression of the skeletal α-actin promoter (Muscat and Kedes, 1987; Brennan and Hardeman, 1993). The expression of the transgene remains high while the endogenous gene is switched off in adult innervated muscle (Moore and Walsh, 1985; Covault and Sanes, 1986).

**Immunohistochemical Analysis of Muscle Cryosections**

Immunohistochemical analysis showed that hNCAM was detected at the sarcolemma on primary myotubes at E15 (Fig. 4 A). During secondary myogenesis, hNCAM is also found expressed at higher levels at sites of primary–secondary myotube apposition than on the rest of the sarcolemma (Fig. 4 C). Fig. 4 also shows the expression of the endogenous mouse NCAM protein (Fig. 4, B and D) which colocalizes with the transgene.

Adult EDL muscle from transgenic animals displayed clear fiber type variations in the expression of the transgene (Fig. 5). An antibody (A4.74) that recognizes MHC isoforms specific to type IIa fibers (Fig. 5 B) clearly indicates that these fibers have a reduced level of expression of hNCAM compared with IIb fibers (Fig. 5 A). We have calculated that the mouse EDL is composed almost exclusively of type II fibers, with a ratio of about 30:70 of IIa/IIb subtypes. In the SOL, which is composed of both type IIa and I fibers, a more uniform staining was observed (data not shown). Taken together with the results obtained from immunoblot analysis (Fig. 2 C), these observations indicate a higher expression level in type IIb fibers compared with type IIa or type I fibers. The apparent intracellular staining for hNCAM is similar to that of the endogenous protein in developing, denervated, or regenerating adult muscle (Moore and Walsh, 1986).

**Impaired Secondary Myogenesis in Transgenic Mice**

Fig. 6 shows examples of laminin-stained muscle fibers from transgenic (Fig. 6 A) versus nontransgenic (Fig. 6 B) animals. The results of fiber counts obtained from four sets of muscle samples from transgenic and nontransgenic littermates are shown in Fig. 6, C and D. At E19 both groups of animals were found to have similar numbers of laminin encased fibers (Fig. 6 C), and H and E–stained muscle fibers (Fig. 6 D). Thus, fiber numbers were 578 ± 23 for transgenic and 532 ± 57 for nontransgenic animals for laminin and 577 ± 52 and 531 ± 41, respectively, for H

---

Figure 4. Immunohistochemical detection of NCAM in developing muscle. Immunostaining with human specific antibody ERIC1 revealed muscle-specific expression of the transgene at E15 (A). The endogenous isoform of NCAM (detected with antibody H28) is also found expressed in myotubes, but higher levels of NCAM are present in nerve (arrowhead, B). Immunostaining of PND1 EDL muscle with hNCAM-specific antibody (C) and mouse NCAM-specific antibody (D) revealed a similar expression profile of the two isoforms in muscle. Both human and mouse NCAM are found concentrated at sites of myotube apposition (arrows). Bar (A and B), 100 μm; (C and D), 10 μm.

Fazeli et al. Skeletal Muscle NCAM 245
and E. However, by PND1 there was a clear decrease in the number of laminin encased versus H and E-stained fibers in the transgenic animals (930 ± 86 versus 1198 ± 43, respectively) when compared with nontransgenic littermates (1199 ± 18 versus 1187 ± 46, respectively). The decrease in fibers surrounded by basal lamina indicates that in the transgenic animals at PND1, the last generation of secondary myotubes remain under the basal lamina of their primary parents. The number of H and E-stained fibers in PND1 transgenic EDL muscle is similar to that found in EDL from adult animals, indicating that secondary myogenesis does not proceed beyond PND1.

To examine whether the perturbation in secondary myogenesis may have resulted from alterations in the expression of other CAMs implicated in this process, we stained hind limb sections from PND1 transgenic and nontransgenic animals with VCAM-1 and VLA4 antibodies. VCAM-1 is expressed on the surface of secondary myoblasts and is thought to interact with VLA-4 expressed on primary myotubes and thus regulate secondary myogenesis (Rosen et al., 1992). Fig. 7 shows immunofluorescence images from the EDL muscle of transgenic (A and C) and nontransgenic (B and D) animals. The number of VCAM-1-positive myoblasts was significantly lower in the transgenic sample (Fig. 7 A). Counting the number of VCAM-1-positive cells within the EDL muscle showed 17.5 ± 4.2 per muscle in transgenic versus 40.3 ± 3.9 in control animals. There was no difference in the number of nuclei per field. VLA-4 staining (Fig. 7, C and D) failed to show any significant changes in expression levels of primary myotubes in the transgenic animals. Staining for M-cadherin, another CAM that is believed to be involved in secondary myogenesis (Zeschnigk et al., 1995) failed to reveal any significant differences between transgenic and nontransgenic animals (Fig. 7, E and F). The reduction in the number of VCAM-1-positive myoblasts at PND1 is
Figure 7. Analysis of the expression of other CAMs in transgenic animals. During secondary myogenesis (PND1) VCAM-1 is expressed on secondary myoblasts in transgenic (A, arrows) and control (B, arrows) animals, but the number of VCAM-1-positive cells was lower in transgenic animals (A). VLA4 was found on primary myotubes in transgenic (C) and control (D) mice at PND1. There were no significant differences between the staining profile of M-cadherin in transgenic (E) and control animals (F) at PND1. Bar, 50 μm.

likely due to an enhancement of myoblast fusion. We therefore examined myofiber size in developing and adult muscles.

Increased Muscle Fiber Size in Transgenic Animals

Analysis of EDL muscle at PND1 revealed that transgenic animals contained myofibers that were on average 16.7% larger than those in nontransgenic littermates (Fig. 8 A). EDL and SOL muscle from adult transgenic and nontransgenic animals also showed a significant increase in myofiber size (Fig. 8, C–E). Analysis of identified fiber types showed that type IIB, IIA, and I fibers all exhibited a statistically significant increase in myofiber radius compared with control muscle. However, this increase was paralleled by the level of expression of the transgene in these fiber subtypes, with the increase in type I/IIa fiber radius (Fig. 8, B and C) being smaller than the increase in type IIB fibers (Fig. 8 D). Changes in the distribution and relative propor-
Figure 8. Changes in myofiber size in transgenic animals. (A) A significant increase in the mean perimeter of myofibers was detected in PND1 EDL muscle of transgenic animals from line AN14 (clear bar) compared with nontransgenic (hatched bar) littermates (n = 4 ± SEM). (B–D) Fiber radius measurements from adult muscle (200 fibers per muscle) were ranked and the mean of each quartile calculated (n = 6 ± sem). Type I fiber radii (B) were measured in the SOL, whereas measurement on type IIa and IIb fibers (C and D, respectively) were obtained from the EDL. In each case transgenic animals display an increase in mean fiber radius at each quartile. The increase in type IIb fibers, however, is larger than that in type IIa and I fibers. This differential increase is correlated with the fiber type difference in the level of expression of the transgene. Similar results were obtained in line AV21. *P = 0.05, **P = 0.01, ***P = 0.001; t test. ○ transgenic; ■ nontransgenic.

Discussion
During muscle development myoblasts divide and fuse under the basal lamina of primary myotubes to give rise to secondary myotubes (Ontell and Kozeka, 1984a,b). These secondary myotubes then separate and acquire their own basal lamina and further rounds of secondary myogenesis occur. A comparison of the number of fibers in adult muscle with the number of primary myotubes at E15 clearly demonstrates that ~85% of fibers are generated by secondary myogenesis (this study; see also Ross et al., 1987; Duxson et al., 1989). The specific mechanism by which secondary myoblasts align alongside primary myotubes and subsequently fuse is unknown. However, a number of studies have implicated a role for CAMs (Menko and Boettiger et al., 1987; Knudsen, 1990; Knudsen et al., 1990; Donalies et al., 1991; Tassin et al., 1991; Mege et al., 1992; Rosen et al., 1992; Moore and Walsh, 1993; Zeschchnigk et al., 1995). In the present study we have extended our in vitro analysis of the involvement of CAMs in muscle development by examining the role of NCAM during secondary myogenesis and myoblast fusion in vivo using a transgenic approach. One attractive hypothesis is that the level of expression of CAMs is a critical determinant of the fusion and alignment of secondary myoblasts and myotubes alongside primary myotubes. We generated transgenic animals using expression constructs containing 2.2 kb of the
A section was counted by extrapolation from the number of fibers in 0.7 mm² of each section, using cross-sectional area measurements. A significant reduction in the number of myofibers was found in the EDL of adult transgenic mice of both lines AN14 and AV21. A smaller reduction was also observed in the soleus (Sol). These data parallel the differences in expression level found in the two muscles. (B) Measurements of the cross-sectional area of muscle sections from transgenic (solid bars) and nontransgenic (hatched bars) mice revealed no significant difference between the two groups (n = 6, ± SEM for all measurements). *P = 0.05, **P = 0.01; t test. □, transgenic; □, nontransgenic.

Figure 9. Adult transgenic mice have unaltered muscle size, but fewer fibers. (A) The total number of myofibers in each muscle section was counted by extrapolation from the number of fibers in 0.7 mm² of each section, using cross-sectional area measurements. Adult animals from VCAM-1 analysis is in agreement with this conclusion. It has been found previously, using a transfection-based approach, that overexpression of the 125-kd hNCAM isoform in C2 muscle cells results in enhanced fusion of secondary myoblasts into secondary myotubes, as a result of the increased expression of NCAM on myotube surfaces, and the observation of a lower number of secondary myoblasts in transgenic animals from VCAM-1 analysis is in agreement with this conclusion. These data parallel the differences in expression level found in the two muscles. (B) Measurements of the cross-sectional area of muscle sections from transgenic (solid bars) and nontransgenic (hatched bars) mice revealed no significant difference between the two groups (n = 6, ± SEM for all measurements). *P = 0.05, **P = 0.01; t test. □, transgenic; □, nontransgenic.

The regulatory region of the human skeletal muscle α-actin gene fused to hNCAM cDNA encoding a 125-kd, GPI-linked isoform of NCAM. The NCAM cDNA also contained the MSD region and either included or excluded the product of the VASE exon. The α-actin promoter has some advantages for this type of work since it directs specific high level expression in myotubes and not myoblasts. Furthermore, the expression level from this promoter gradually increases between E15 and postnatal week 2 resulting in high level transgene expression at times of development and plasticity of skeletal muscle.

There are presently no specific markers of secondary myotubes that would allow their unequivocal identification. However, we took advantage of the fact that secondary myotubes develop under the basal lamina of their “parent” primary myotubes. The number of laminin-encased fibers was therefore compared with the number of fibers counted on H and E-stained sections of developing EDL muscle. Fibers enclosed in basal lamina are either primary myotubes with or without an associated secondary myotube or are separated secondary myotubes. Thus, if secondary myotube separation was hindered, a discrepancy should occur between the total number of fibers (H and E sections) and the number of fibers enclosed by basal lamina as defined by laminin staining. There was a significant decrease in the number of fibers surrounded by basal lamina in the transgenic animals at PND1, whereas the total number of fibers was unaltered. The expression levels of a number of other CAMs believed to be involved in secondary myogenesis, such as VCAM-1, VLA-4, and M-cadherin, were also studied in the hNCAM-expressing transgenic animals. No change was found in the distribution or the level of expression of VLA-4 and M-cadherin. However, there was a decreased number of VCA-1-positive secondary myoblasts at PND1, indicating a depletion of this population of cells. These findings thus indicate that the precise control of NCAM expression levels at primary–secondary myotube appositions is likely to be an important step in the regulation of secondary myoblast fusion and myotube separation. The hNCAM-expressing transgenic animals showed no obvious signs of muscular dysfunction and an examination of various muscles showed no obvious abnormalities. Cryosections of EDL and SOL muscles from transgenic and nontransgenic animals were compared by morphometric analysis. Adult animals from lines AV21 and AN14 revealed a significant decrease in the total number of fibers in each muscle examined. This was accompanied by an overall increase in myofiber size first detected at PND1. This increase is likely due to enhanced fusion of secondary myoblasts into secondary myotubes, as a result of the increased expression of NCAM on myotube surfaces, and the observation of a lower number of secondary myoblasts in transgenic animals from VCAM-1 analysis is in agreement with this conclusion. The adhesive function of NCAM is not markedly influenced by the presence of the VASE exon (Doherty et al., 1992), though NCAM transcripts containing the VASE exon have been shown to be less effective in promoting neurite outgrowth in vitro (Doherty et al., 1992). Indeed, this isoform of NCAM is specifically expressed in cardiac muscle, which shows a lower expression of the transgene. Fiber type variations in hNCAM expression levels were evident as early as E18.

AV21 animals express an alternative isoform of hNCAM, namely one that contains the 10-amino acid product of the alternatively spliced VASE exon in its extracellular domain. This transcript is thought to be specific to cardiac and neuronal tissues, although low levels of VASE containing NCAM isoforms have been detected in skeletal muscle (Anderson et al., 1993). The adhesive function of NCAM is not markedly influenced by the presence of the VASE exon (Doherty et al., 1992), though NCAM transcripts containing the VASE exon have been shown to be less effective in promoting neurite outgrowth in vitro (Doherty et al., 1992). Indeed, this isoform of NCAM is specifically expressed in cardiac muscle, which shows a lower expression of the transgene. Fiber type variations in hNCAM expression levels were evident as early as E18.
thought to be partly responsible for the developmental loss of responsiveness to NCAM. Recent observations have also indicated that, in neuronal cells, intracellular signaling by NCAM (without VASE) is at least partly through the activation of the FGF receptor (Williams et al., 1994). NCAM transcripts containing the VASE exon appear to be unable to activate this pathway. There was no difference between the muscle phenotype of animals overexpressing NCAM, irrespective of whether they contained the VASE exon or not.

In summary, we have found that increased expression of the 125-kd, GPI-anchored form of NCAM in skeletal muscle under the control of the skeletal muscle α-actin promoter results in a developmental perturbation of secondary myogenesis first in that they do not effectively separate from primary myotubes, and second there is an enhancement of secondary myoblast fusion. The data indicate that the expression of NCAM in the sarcolemma, along with other CAMs, plays an important role during skeletal myogenesis. The strategy developed here will be useful in examining the role of other CAMs in myogenesis. In particular, members of the cadherin family such as N- and M-cadherin are of interest as truncated (dominant negative) forms would most likely affect myoblast fusion.

This work was supported by the Wellcome Trust and the Muscular Dystrophy Group of Great Britain.

Received for publication 12 January 1996 and in revised form 12 July 1996.

References
Anderson, A.M., M. Olsen, D. Zhernosekov, H. Gaardsvoll, L. Krog, D. Linnesmo et al., 1994. NCAM transcripts containing the VASE exon from skeletal muscle. EMBO (Eur. Mol. Biol. Organ.) J. 13:625-632.
Bouron, S.P., K. Kashi, F.S. Walsh, L.H. Rowett, W. Putti, V. Elsom, S.E. Moore, C.H. Barton, and F.S. Walsh. 1990. Complete sequence and in vitro expression of a tissue-specific phosphatidylinositol-linked NCAM isoform from skeletal muscle. Development (Camb.). 104:165-173.

McCormick, D., H. Chong, C. Hobbs, C. Datta, and P.A. Hall. 1993. Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1. Histopathology (Oxf). 23:355-360.
Mege, R.M., R. Goudou, C. Diaz, M. Nicolet, L. Garcia, G. Geraud, and F. Rieger. 1992. N-cadherin and NCAM in myoblast fusion: comparison localisation and effect of blockade by antibodies and liposomes. J. Cell Biol. 103:897-906.

Knudsen, K.A., S. McElwae, and L. Myers. 1990. A role for the neural cell adhesion molecule, NCAM, in myoblast interaction during myogenesis. Dev. Biol. 138:159-168.
Lyons, G., R. Moore, O. Yabara, M.E. Buckingham, and F.S. Walsh. 1992. Expression of NCAM isoforms during skeletal myogenesis in the mouse embryo. Dev. Dynamics. 194:90-104.
McCormick, D., H. Chong, C. Hobbs, C. Datta, and P.A. Hall. 1993. Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1. Histopathology (Oxf). 23:355-360.
Mege, R.M., R. Goudou, C. Diaz, M. Nicolet, L. Garcia, G. Geraud, and F. Rieger. 1992. N-cadherin and NCAM in myoblast fusion: compared localisation and effect of blockade by antibodies and liposomes. J. Cell Biol. 103:897-906.
Menko, A.S., and D. Boettiger. 1987. Occupation of the extracellular matrix receptor, integrin, is a control point for myogenic differentiation. Cell. 51:51-57.
Moore, S.E., and F.S. Walsh. 1985. Specific regulation of NCAM/D2-CAM cell adhesion molecule during skeletal muscle development. EMBO (Eur. Mol. Biol. Organ.) J. 4:623-630.
Moore, S.E., and F.S. Walsh. 1986. Nerve dependent regulation of neural cell adhesion molecule expression in skeletal muscle. Neurosci. Lett. 2:499-505.
Moore, S.E., and F.S. Walsh. 1993. The cell adhesion molecule M-cadherin is specifically expressed in developing and regenerating, but not denervated skeletal muscle. Development (Camb.). 117:1409-1420.
Moore, S.E., J. Thompson, V. Kirkness, J.G. Dickson, and F.S. Walsh. 1987. Knockout of neural muscle cell adhesion molecule NCAM changes in protein and mRNA species during myogenesis of cell lines. J. Cell Biol. 105:1377-1386.

Moore, S.E., and F.S. Walsh. 1986. Nerve dependent regulation of neural cell adhesion molecule expression in skeletal muscle. Neurosci. Lett. 2:499-505.
Moore, S.E., and F.S. Walsh. 1993. The cell adhesion molecule M-cadherin is specifically expressed in developing and regenerating, but not denervated skeletal muscle. Development (Camb.). 117:1409-1420.
Moore, S.E., J. Thompson, V. Kirkness, J.G. Dickson, and F.S. Walsh. 1987. Knockout of neural muscle cell adhesion molecule NCAM changes in protein and mRNA species during myogenesis of cell lines. J. Cell Biol. 105:1377-1386.

Muscat, G.E.O., and L. Kedes. 1987. Multiple 5'-flanking regions of the human NCAM gene in mice results in size reduction of the olfactory bulb and deficits in spatial learning. J. Cell Biol. 107:743-750.

Onellis, M., and K. Koceka. 1984a. The organogenesis of murine striated muscle: a cytoarchitectural study. Am. J. Anat. 171:133-148.
Onellis, M., and K. Koceka. 1984b. Organogenesis of the mouse extensor digitorum longus muscle: a quantitative study. Am. J. Anat. 171:149-161.
Peck, D., and F.S. Walsh. 1993. Differential effects of over expressed NCAM isoforms on myoblast fusion. J. Cell Biol. 123:1587-1595.
Peck, D., and F.S. Walsh. 1993. Differential effects of over expressed NCAM isoforms on myoblast fusion. J. Cell Biol. 123:1587-1595.
Peck, D., and F.S. Walsh. 1993. Differential effects of over expressed NCAM isoforms on myoblast fusion. J. Cell Biol. 123:1587-1595.
Ross, J.J., L. Duxson, and A.J. Harris. 1987. Formation of primary and secondary myotubes in rat lumbar muscles. Development (Camb.). 100:383-394.
Sambrook, J., E.F. Fritsch, and T. Maniatis. 1989. Molecular Cloning: A Laboratory Manual. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. 545 pp.
Small, S.J., and R. Akesou. 1990. Expression of the unique NCAM VASE exon in developing and adult skeletal muscle. J. Cell Biol. 107:743-750.

The Journal of Cell Biology, Volume 135, 1996
Thompson, J., G. Dickson, S.E. Moore, H.J. Gower, W. Putt, J. Kenimer, and F.S. Walsh. 1989. Alternative splicing of the neural cell adhesion molecule (NCAM) gene generates variant extracellular domain structure in skeletal muscle and brain. *Genes & Dev.* 3:348-357.

Walsh, F.S., and P. Doherty. 1991. Structure and function of the gene for neural cell adhesion molecule. *Semin. Neurosci.* 3:271–284.

Walsh, F.S., and P. Doherty. 1994. Cell biology of muscle. In Disorders of Voluntary Muscle. J. Walton, G. Karpati, and D. Hilton-Jones, editors. Churchill Livingston, Edinburgh. 35-61.

Walsh, F.S., J. Furness, S.E. Moore, S.V. Ashton, and P. Doherty. 1992. Use of the NCAM-VASE exon by neurones is associated with a specific down-regulation of NCAM dependent neurite outgrowth in the developing cerebellum and hippocampus. *J. Neurochem.* 59:1959-1962.

Williams, E.J., J. Furness, F.S. Walsh, and P. Doherty. 1994. Activation of the FGF receptor underlies neurite outgrowth stimulated by L1, N-CAM, and N-cadherin. *Neuron.* 13:583–594.

Zeschnigk, M., D. Kozian, C. Kuch, M. Schmoll and A. Starzinski-Powitz. 1995. Involvement of M-cadherin in terminal differentiation of skeletal muscle cells. *J. Cell Sci.* 108:2973–2981.